Skip to main content Accessibility help
×
Home

Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine

  • Jean Lachaine (a1) (a2), Catherine Beauchemin (a2), Joëlle Bibeau (a2), Julie Patenaude (a2), Pratap Chokka (a3), Jean Proulx (a4) and Joanna Bougie (a4)...

Abstract

Objective

The AtWoRC study is an interventional, open-label Canadian study that demonstrated significant improvements in cognitive function and workplace productivity in patients with major depressive disorder (MDD) treated with vortioxetine for a current major depressive episode. The objective of the present analysis was to assess the Canadian economic impact of improved workplace productivity based on the AtWoRC study results.

Methods

The economic impact of improved productivity in patients with MDD treated with vortioxetine was assessed over a 52-week period considering productivity loss due to absenteeism and presenteeism using the standard human capital approach and an employer’s perspective. Absenteeism was measured with the Work Productivity and Activity Impairment questionnaire; and presenteeism with the Work Limitation Questionnaire. Productivity gains following treatment initiation with vortioxetine were estimated using the difference from baseline.

Results

In the AtWoRC study, patients at baseline reportedly missed, in the past 7 days, an average of 8.1 h due to absenteeism and 3.0 h due to presenteeism. Following 52 weeks of treatment with vortioxetine, patients reportedly missed an average of 4.9 h due to absenteeism and 2.0 h due to presenteeism. This improved workplace productivity translated into savings of C$110.64 for 1 week of work following 52 weeks of treatment. The cumulative 52-week economic impact showed potential savings of C$4,550 when factoring in the cost of therapy.

Conclusion

This study suggested that workplace productivity gain due to an improvement in symptoms of MDD following treatment with vortioxetine will lead to substantial cost savings for the Canadian economy.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

*Address correspondence to: Jean Lachaine, PeriPharm, Inc., 600-5858 chemin de la Côte-des-Neiges, Montreal, Quebec H3S 1Z1, Canada. (Email: jean.lachaine@peripharm.com)

Footnotes

Hide All

All authors were involved at all stages of manuscript development, approved the final version of the manuscript to be published, and agreed to act as guarantors of the work. We would also like to thank Kimberly Guinan for her contribution to the data analysis.

Footnotes

References

Hide All
1. Collins, JJ, Baase, CM, Sharda, CE, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med. 2005; 47(6): 547557.
2. Greenberg, PE, Fournier, A-A, Sisitsky, T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015; 76(2): 155162.
3. Greenberg, PE, Kessler, RC, Birnbaum, HG, et al. The economic burden of depression in the United States: How did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64(12): 14651475.
4. Lam, RW, McIntosh, D, Wang, J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 1. Disease burden and principles of care. Can J Psychiatry. 2016; 61(9): 510523.
5. Patten, SB, Williams, JV, Lavorato, DH, et al. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can J Psychiatry. 2015; 60(1): 2330.
6. Lim, K-L, Jacobs, P, Ohinmaa, A, et al. A new population-based measure of the economic burden of mental illness in Canada. Chronic Dis Can. 2008; 28(3): 9298.
7. Stonebridge, C, Sutherland, G. Healthy Brains at Work: Estimating the Impact of Workplace Mental Health Benefits and Programs. The Conference Board of Canada, 1, 2016.
8. National Institute of Mental Health. Depression. October 2016. https://www.nimh.nih.gov/health/topics/depression/index.shtml, Access: 2017.
9. Lam, RW, Kennedy, SH, McIntyre, RS, et al. Cognitive dysfunction in major depressive disorder: Effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014; 59(12): 649654.
10. Conradi, HJ, Ormel, J, de Jonge, P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: A 3-year prospective study. Psychol Med. 2011; 41(6): 11651174.
11. Fava, M, Graves, LM, Benazzi, F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006; 67(11): 1754.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub, United States; 2013.
13. Thase, ME, Mahableshwarkar, AR, Dragheim, M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol : J Eur Coll Neuropsychopharmacol. 2016; 26(6): 979993.
14. Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet (London, England). 2018; 391(10128): 13571366.
15. Alvarez, E, Perez, V, Dragheim, M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012; 15(5): 589600.
16. Baldwin, DS, Loft, H, Dragheim, M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012; 22(7): 482491.
17. Boulenger, J-P, Loft, H, Florea, I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012; 26(11): 14081416.
18. Jain, R, Mahableshwarkar, AR, Jacobsen, PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2012; 16(2): 313321.
19. Katona, C, Hansen, T, Olsen, CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27(4): 215223.
20. Mahableshwarkar, AR, Jacobsen, PL, Chen, Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29(3): 217226.
21. Kennedy, SH, Lam, RW, McIntyre, RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Can J Psychiatry. 2016; 61(9): 540560.
22. Chokka, P, Bougie, J, Rampakakis, E, et al. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. 2018; 110. doi:10.1017/s1092852918000913
23. Chokka, P, Bougie, J, Proulx, J, et al. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr. 2019; 112. doi:10.1017/S1092852919000786
24.Reilly Associates health outcomes research. http://www.reillyassociates.net. Accessed January 11, 2018.
25. Despiegel, N, Danchenko, N, Francois, C, et al. The use and performance of productivity scales to evaluate presenteeism in mood disorders. Value Health. 2012; 15(8): 11481161.
26. Lerner, D, Amick, III Rogers, BC , WH, et al. The work limitations questionnaire. Med Care. 2001; 39(1): 7285.
27. Statistics Canada. Average weekly hours (including overtime) for employees paid by the hour, by province and territory. 2017; http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr82-eng.htm accessed date: December 2017.
28. Lofland, JH, Pizzi, L, Frick, KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004; 22(3): 165184.
29. Statistics Canada. Table 282-0073 7: Labour Force Survey estimates (LFS), wages of employees by job permanency, union coverage, sex and age group, unadjusted for seasonality. http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=2820073&tabMode=dataTable&p1=1&p2=-1&srchLan=-1&pattern=wage.
30. Lundbeck Canada Inc. Vortioxetine—Product monograph. Updated July 8th 2016. 2016.
31. Vieta, E, Loft, H, Florea, I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. Eur Neuropsychopharmacol. 2017; 27(9): 877884. doi:10.1016/j.euroneuro.2017.06.012
32. Kessler, RC, Akiskal, HS, Ames, M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry. 2006; 163(9): 15611568.
33. Romera, I, Perez, V, Menchón, J, et al. Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study. Eur Psychiatry. 2010; 25(1): 5865.
34. Van den Hout, W. The value of productivity: Human-capital versus friction-cost method. Ann Rheum Dis. 2010; 69(Suppl 1): i89i91.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed